Get the Stockscreener App
12.94
2.54%
0.32
Viridian Therapeutics Inc stock is traded at $12.94, with a volume of 596.59K.
It is up +2.54% in the last 24 hours and up +2.29% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$12.62
Open:
$12.63
24h Volume:
596.59K
Relative Volume:
0.67
Market Cap:
$1.06B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-3.0447
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
+4.44%
1M Performance:
+2.29%
6M Performance:
-35.75%
1Y Performance:
-11.55%
1-Day Range:
$12.48
$13.09
1-Week Range:
$12.07
$13.38
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
12.94 | 1.01B | 288.00K | -228.06M | -168.82M | -4.25 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Northern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Dimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by The Manufacturers Life Insurance Company - Defense World
Viridian Therapeutics (VRDN) to Release Quarterly Earnings on Wednesday - Defense World
Q2 EPS Estimate for Viridian Therapeutics Lowered by Analyst - Defense World
Wedbush Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst - Defense World
B. Riley Boosts Earnings Estimates for Viridian Therapeutics - Defense World
Needham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - The AM Reporter
JMP Securities Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - Defense World
Royal Bank of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $45.00 - Defense World
Q1 Earnings Estimate for VRDN Issued By HC Wainwright - Defense World
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - Defense World
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - BioSpace
Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus
What 5 Analyst Ratings Have To Say About Viridian Therapeutics - Benzinga
FDA Grants Breakthrough Therapy Status to Viridian's (VRDN) Veligrotug | VRDN Stock News - GuruFocus
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Target Price Adjusted by RBC Capita - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Rating | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Update by JMP Securities | VRDN Stock News - GuruFocus
Viridian Therapeutics (VRDN) Price Target Reduced Amid Market Concerns | VRDN Stock News - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | V - GuruFocus
Needham Maintains Buy Rating on Viridian Therapeutics (VRDN) | VRDN Stock News - GuruFocus
Viridian Therapeutics price target lowered to $38 from $42 at Citizens JMP - TipRanks
Thyroid Eye Disease Market Top Companies StudyHorizon - openPR.com
Bullish Viridian Therapeutics Insiders Loaded Up On US$616.3k Of Stock - simplywall.st
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics (VRDN) Sees Price Target Adjustment by Citizens JMP | VRDN Stock News - GuruFocus
Viridian Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating - TipRanks
Viridian Therapeutics Inc (VRDN)’s Market Momentum: Closing Strong at 13.12, Down -3.67 - DWinneX
Stifel maintains Buy on Viridian Therapeutics, $41 target By Investing.com - Investing.com India
Viridian Therapeutics Shares Fall After Q1 Net Loss Widens, Revenue Flat - marketscreener.com
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats By Investing.com - Investing.com Nigeria
Viridian Therapeutics shares fall as Q1 loss narrows, revenue beats - Investing.com
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Q1 2025 Financial Results - TradingView
Earnings Flash (VRDN) Viridian Therapeutics Posts Q1 Net Loss $0.87 a Share, vs. FactSet Est of $1 Loss - marketscreener.com
How to Take Advantage of moves in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq L - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc [NASDAQ: VRDN] Sees Increase in Stock Value - knoxdaily.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharma - Barchart.com
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):